David Turkaly
Stock Analyst at Citizens
(2.15)
# 2,892
Out of 5,141 analysts
144
Total ratings
38.64%
Success rate
-3.74%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Upgrades: Market Outperform | $440 | $380.23 | +15.72% | 4 | Dec 19, 2025 | |
| TELA TELA Bio | Maintains: Market Outperform | $7 → $5 | $0.72 | +596.96% | 7 | Nov 14, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $3.78 | +111.64% | 6 | Nov 12, 2025 | |
| AXGN Axogen | Maintains: Market Outperform | $26 → $34 | $35.30 | -3.68% | 8 | Oct 30, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $16.96 | +47.41% | 12 | Oct 10, 2025 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $112 → $73 | $73.87 | -1.18% | 9 | Aug 7, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $13.87 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $90.59 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $61.19 | +63.43% | 12 | May 20, 2025 | |
| STE STERIS | Maintains: Market Outperform | $265 → $280 | $250.65 | +11.71% | 18 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $35 → $25 | $12.21 | +104.75% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $22.73 | +141.97% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $98.75 | +26.58% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $388.60 | +28.67% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $115.45 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $15.48 | +106.72% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $5.14 | +211.28% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.29 | +132.56% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $6.80 | -26.47% | 1 | Oct 6, 2017 |
Stryker
Dec 19, 2025
Upgrades: Market Outperform
Price Target: $440
Current: $380.23
Upside: +15.72%
TELA Bio
Nov 14, 2025
Maintains: Market Outperform
Price Target: $7 → $5
Current: $0.72
Upside: +596.96%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $3.78
Upside: +111.64%
Axogen
Oct 30, 2025
Maintains: Market Outperform
Price Target: $26 → $34
Current: $35.30
Upside: -3.68%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $16.96
Upside: +47.41%
Lantheus Holdings
Aug 7, 2025
Maintains: Market Outperform
Price Target: $112 → $73
Current: $73.87
Upside: -1.18%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $13.87
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $90.59
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $61.19
Upside: +63.43%
STERIS
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $250.65
Upside: +11.71%
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $12.21
Upside: +104.75%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $22.73
Upside: +141.97%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $98.75
Upside: +26.58%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $388.60
Upside: +28.67%
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $115.45
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.48
Upside: +106.72%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $5.14
Upside: +211.28%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.29
Upside: +132.56%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $6.80
Upside: -26.47%